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Early response to treatment has been shown to be an important prognostic factor of childhood acute lymphoblastic leukemia (ALL)
patients in Western studies. We studied this factor in the setting of a low-income province in 165 patients treated on Indonesian
WK-ALL-2000 protocol between 1999 and 2006. Poor early response, defined as a peripheral lymphoblasts count of ≥1000/µL
after 7 days of oral dexamethasone plus one intrathecal methotrexate (MTX), occurred in 19.4% of the patients. Poor responders
showed a higher probability of induction failures compared to good responders (53.1% versus 23.3%, P < 0.01), higher probability
of resistant disease (15.6% versus 4.5%, P = 0.02), shorter disease-free survival (P = 0.034; 5-year DFS: 24.9%± 12.1% versus
48.6%± 5.7%), and shorter event-free survival (P = 0.002; 5-year EFS: 9.7%± 5.3% versus 26.3%± 3.8%). We observed that the
percentage of poor responders in our setting was higher than reported for Western countries with prednisone or prednisolone as
the steroids. The study did not demonstrate a significant additive prognostic value of early response over other known risk factors
(age and white blood cell count) for DFS and only a moderately added value for EFS.
1. Introduction
International studies in the United States and Europe have
shown the importance of clinical and biologic character-
istics as prognostic factors in childhood ALL. Risk-based
treatment has led to a significantly increased cure rate to
more than 80% [1], and poor early response to treatment
has been well known as a strong predictor for adverse
outcome in childhood ALL [2–9]. Poor responder patients
with persistence of lymphoblasts of 1,000/µL or more in
the peripheral blood on day 8 or 25% or more in marrow
on day 14 of treatment show poorer outcomes than the
good responder patients [2, 10, 11]. This measurement
allows early detection of a patient subpopulation at high
risk that is not classified as such by National Cancer
Institute (NCI), Rome criteria for risk stratification [12].
Advance technique that refines morphology examination
in assessing treatment response is minimal residual disease
(MRD) measurement. MRD-based stratification was proven
predictive for clinical outcomes in some large series study
[13–17].
In comparison with marrow aspiration, peripheral blast
measurement is much more practical, less invasive, and
cheaper, while MRD evaluation using flow cytometric or
PCR method is not available in low-income countries. There
is a lack of data related to the measurement of the early
response to treatment as predictor for adverse outcome
obtained from developing countries, all come from Western
countries. We therefore conducted this study in Yogyakarta,
Indonesia in the setting of a low-income country with cure
rates in the order of 20–30% in patients treated with a
dexamethasone-based protocol.
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2. Materials and Methods
2.1. Patients. This study enrolled newly diagnosed childhood
ALL patients treated with WK-ALL-2000 protocol in the
Pediatric Cancer Unit of the Dr. Sardjito Teaching Hos-
pital (DSH) of the Universitas Gadjah Mada, Yogyakarta,
Indonesia during the period of February 1999 to March
2006. The diagnosis of ALL was based on morphology and
cytochemistry of marrow specimens that were assessed by
two experienced technicians. The inclusion criteria were
age range 0–14, FAB morphology L1 or L2, no previous
treatment with steroids or leukemia treatment and parents
approval. Patients were classified into the high-risk (HR)
group based on age of less than 1 year or more than 10 years,
WBC count 50,000/µL or more, and presence of mediastinal
mass or central nervous system (CNS) involvement. The
others were classified as standard risk (SR) group. Treatment
started with one-week dexamethasone (6mg/m2) plus one
intrathecal MTX on day 1 (dose according to age). Patients
were moved from SR to HR group and treated accordingly
when they showed poor early response to treatment. Of
209 newly diagnosed childhood ALL patients admitted to
DSH, 30 patients were excluded because they did not meet
inclusion criteria (21) or moved to another protocol during
treatment (9). Of the remaining 179 eligible patients, 14
patients were excluded because they did not have data
regarding early response to treatment due to early death
caused by toxic condition of leukemia (9) or abandonment
(3) before evaluation of early response was performed and
the measurement was not conducted in 2 patients. Analysis
was done on 165 patients at the end of observation on July
31, 2010.
2.2. Treatment Protocol. All patients were treated on WK-
ALL-2000 protocol (Figure 1). It was the first Indonesian
national protocol for childhood ALL [18] adapted from the
dexamethasone-basedDutch protocol ALL-VI [19]. The pro-
tocol consisted of 1-week prephase, continued with 5-week
induction, 4-week consolidation and blocks in maintenance
treatment of 95 weeks in SR patients. HR patients received
additional one dose of daunorubicin in induction treatment
plus a reinduction treatment (4 weeks) that was inserted
after the consolidation treatment, otherwise the drugs and
schedule were similar between the HR and SR protocols.
Infants less than 1 year of age were grouped and treated as
HR because a separate protocol for this group of patients
was not yet developed in our institution. Patients were also
randomized to receive or not to receive 3 extra doses of L-
Asparaginase during consolidation treatment (manuscript in
preparation).
2.3. Early Response to Treatment Measurement. Early re-
sponse to treatment was measured as an absolute number
of peripheral lymphoblasts at day 8 of induction treatment,
after administration of 7 days oral dexamethasone 6mg/m2,
but adjusted to WBC count to prevent tumor lysis syn-
drome. Patients with a WBC count at diagnosis between
20,000/µL–50,000/µL started with 2mg/m2 dexamethasone,
and increased the dose in 4 days to 6mg/m2; WBC count
between 50,000/µL–100,000/µL started with 1mg/m2 dex-
amethasone and increased the dose in 5 days to 6mg/m2.
Patients with WBC count of more than 100,000/µL started
at 0.5mg/m2. One dose of age-adjusted intrathecal MTX
was scheduled on day 1, that was 6, 8, 10 or 12mg for age
less than 1, ≥1-2, ≥2-3 or ≥3 year(s), respectively. In our
situation the intrathecal MTX administration was not given
on day 1 of treatment in some cases due to unsuccessful
lumbar puncture or drug availability. Analysis of patients
record learned that intrathecal MTX was given on days 0–2
in 43%, days 3–5 in 20%, after day 5 in 9% of patients, and in
28% the day of administration was not noted in the patients
record. Patients were classified as good responders when the
absolute peripheral lymphoblasts count at day 8 was less than
1,000/µL and poor responder when 1,000/µL or more.
2.4. Outcome Variables and Statistical Analysis. The outcome
variables evaluated were complete remission (CR) achieve-
ment, death, abandonment of treatment, and development
of relapse. Complete remission was determined at the end
of induction (day 42 of treatment) as the absence of
lymphoblasts in peripheral blood and cerebrospinal fluid,
less than 5% lymphoblasts in active hematopoetic marrow
with no evidence of localized disease anywhere. Resistant
disease was defined as failure to achieve CR. Abandonment
of treatment was ascertained when treatment was initiated
but not completed. Relapse was defined as recurrence of
lymphoblasts or localized infiltration of lymphoblasts at any
site after CR. Disease-free survival (DFS) was calculated
as the interval between date of entering treatment and
date of failure to achieve CR (resistant disease) or to a
relapse. Patients who abandoned treatment were considered
failures at date of abandonment and were censored at the
time they were last seen. Event-free survival (EFS) was
calculated as the interval between date of entering treatment
and date of an event that occurred first: induction failure,
death, abandonment, or relapse. Induction failures consist
of death and abandonment during induction and resistant
disease. DFS and EFS analyses were performed using Kaplan-
Meier method and survival of poor responders and good
responders were compared using the log rank test. Possible
risk factors were first identified in univariate survival anal-
yses. All risk factors with a P value less than 0.10 in the
univariate analyses were included in a multivariate analysis.
The multivariate analysis was done using Cox regression.
All data were analyzed using Statistical Package for Social
Sciences (SPSS) program version 13, and a two-sided P value
less than.05 was used as level for statistically significance.
3. Results
Characteristics of the patients are shown in Table 1. Poor
responder patients were 32 (19.4%) of 165 patients, con-
sisting of 7 SR patients who moved to HR group on day
8 of treatment, 3 standard risk patients who remained
in SR group by mistake, and 22 patients who fulfilled
already HR criteria at diagnosis. A higher percentage of poor
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Figure 1: The Indonesian WK-ALL-2000 protocol for childhood ALL. Induction and consolidation treatment of standard risk protocol (a).
One dose of daunorubicin (Dnr) in induction plus a reinduction treatment was added in high-risk protocol (b). The maintenance treatment
was similar between the standard risk and high risk protocols (c). 3A/0A were group of patients who received/did not receive 3 extra doses
of L-asparaginase during consolidation treatment.
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Table 1: Characteristics of patients.
Poor responder (N = 32) Good responder (N = 133) Total (N = 165)
P value
n (%) n (%) n (%)
Risk group
Standard risk 10a 31.3 90 67.7 100 60.6
<0.01
High risk 22 68.8 43 32.3 65 39.4
Gender
Girl 14 43.8 54 40.6 68 41.2
0.75
Boy 18 56.3 79 59.4 97 58.8
Age group (NCI criteria)b
Standard risk 21 65.6 118 88.7 139 84.2
<0.01
High risk 11 34.4 15 11.3 26 15.8
WBC count (/µL)
<50,000 14 43.8 111 83.5 125 75.8
<0.01≥50,000 18 56.2 22 16.5 40 24.2
Median (range) 70,000 (2,000–424,000) 7,800 (600–346,000)
Peripheral lymphoblasts count at diagnosis (%)c
0–49 7 21.9 65 49.6 72 44.2
<0.01
50–100 25 78.1 66 50.4 91 55.8
a
Of 10 standard risk patients with poor response, 7 moved to high risk and 3 were still in standard risk by mistake. bStandard risk (1–9 years), high risk (10–
14 years and infant <1 year (including 1 patient)). cData not available in 2 patients.
Table 2: Treatment outcome by groups of early response to treatment measured at day 8.
Good responder (N = 133) Poor responder (n = 32) Total (N = 165)
OR 95% CI P value
n (%) n (%) n (%)
Induction treatment
Complete remission 102 76.7 15 46.9 117 70.9
Induction failures 31 23.3 17 53.1 48 29.1 3.73a 1.67–8.32 0.0011
Abandonment 14 10.5 6 18.8 20 12.1 2.91a 0.97–8.75 0.092
Death 11 8.3 6 18.8 17 10.3 3.71a 1.19–11.51 0.032
Resistant disease 6 4.5 5 15.6 11 6.7 5.67a 1.54–20.89 0.012
Adverse event after CR
Continuous CR 33 32.4 3 20.0 36 30.8
Relapse 38 37.3 7 46.7 45 38.5 2.02b 0.48–8.47 0.502
Death 16 15.7 3 20.0 19 16.2 2.06b 0.37–11.38 0.402
Abandonment 15 14.7 2 13.3 17 14.5 1.47b 0.22–9.71 0.652
Site of relapse 38 7
Isolated hematological 28 73.7 5 71.4 33 73.4
Isolated CNS 7 18.5 1 14.3 8 17.8
Other 3 7.8 1 14.3 4 9.8
OR: odds ratio for poor responders relative to good responders; CI: confidence interval; CR: complete remission. aORs for any induction failure and specific
induction failures (CR during induction is taken as the reference outcome category). bORs for first event after CR (continuous CR is taken as the reference
outcome category). 1Chi-square test. 2Fisher exact test.
responders as compared to good responders fell into HR
group (68.8% versus 32.3%, P < 0.01), age category 10–
14 years (34.4% versus 11.3%, P < 0.01), WBC count at
diagnosis category ≥ 50,000/µL (56.2% versus 16.5%, P <
0.01), and percentage of peripheral blasts count at diagnosis
category 50–100% (78.1% versus 50.4%, P < 0.01). The
median WBC count at diagnosis was much higher in poor
responder patients (70,100 (range: 2,000–424,000) versus
7,800 (range: 600–346.000) per µL, Mann-Whitney U test,
P = 0.01). Treatment outcome by groups of early response to
treatment measured at day 8 is shown in Table 2. Complete
remission was achieved in 117 (70.9%) of 165 patients: 15
(46.9%) of 32 in poor responder and 102 (70.9%) of 133
in good responders patients. Poor responders were more
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likely to experience induction failures than good responders
(OR = 3.73, 95% CI 1.67–8.32, P = 0.001). A post hoc
analysis for comparing the probability of occurrence of the
diﬀerent type of induction failures between poor and good
responder groups showed a higher odds for resistant disease
and death (both relative to complete remission) in the poor
responder group (P = 0.01 and P = 0.03, resp.). The odds for
abandonment did not diﬀer between the groups (P = 0.09).
After achieving CR, the most relevant adverse event was
relapse (38.5%), followed by death in remission (16.2%) and
abandonment (14.5%). Although not statistically significant,
relapse and death in remission were higher in poor respon-
ders than in good responder patients. Twenty-nine (65%) of
all 45 relapse cases occurred during treatment, mostly in the
maintenance phase in 25 (55%) of cases. Thirty-three (73%)
relapses occurred as isolated hematological relapses.
When establishing the relation between early response to
treatment and survival using Kaplan-Meier analyses it was
found that poor responder patients had a significantly lower
DFS (P = 0.034) and EFS (P = 0.002) (Figures 2 and 3).
The 5-year DFS probability was 24.9% ± 12.1% for poor
responders compared to 48.6%± 5.7% for good responders.
The 5-year EFS probabilities were 9.7%± 5.3% and 26.3%±
3.8% for poor responders and good responders, respectively.
Univariate analysis showed that age at diagnosis, WBC
count at diagnosis and early response to treatment were
predictive for DFS and EFS (Tables 3 and 4). Further
multivariable analysis using forward selection (with age at
diagnosis, WBC count, and early response) revealed that age
at diagnosis remained as the only independent prognostic
factor for DFS (HR 2.63, 95% CI 1.32–5.26, P = 0.006) as
presented in Table 3.
Age at diagnosis and WBC count were identified as
independent prognostic factors for EFS (HR for age 1.75,
95% CI: 1.10–2.79, P = 0.018; HR for WBC count 1.77,
95% CI: 1.18–2.66, P = 0.006), see Table 4. When early
response was added to these models the association with
survival was not significant for DFS and only borderline
significant for EFS (DFS: HR for early response corrected
for age 1.75, 95% CI: 0.89–3.46, P = 0.105; EFS: HR for
early response corrected for age and WBC count category
1.53, 95% CI: 0.98–2.39, P = 0.062), indicating that part of
the association between early response and survival that was
found in the univariate analyses could be explained through
its association with other risk factors.
4. Discussion
Early response to treatment has been associated with prog-
nosis in childhood ALL [2–5, 9, 20, 21] as well as in
subpopulations of ALL such as infants [22], T-cell ALL
[23, 24], and Philadelphia chromosome-positive (Ph+) ALL
[25, 26]. All studies revealed that poor responders with
persistence of a relatively high number of lymphoblasts in the
peripheral blood after 7 days treatment or in bone marrow
after 14 days treatment had significantly poorer outcome
than good responder patients. A study by Rautonen et al. [27]
revealed that the longer the time required for disappearance
0 2 4 6 8 10 12
Years
0
0.2
0.4
0.6
0.8
1
D
is
ea
se
-f
re
e 
su
rv
iv
al
P = 0.03
Figure 2: Kaplan-Meier survival curve for disease-free survival by
early response to dexamethasone treatment. The events are resistant
disease and relapses. The continuous line represents good respon-
ders (n = 133) and the dashed line represents poor responders
(n = 32).
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Figure 3: Kaplan-Meier survival curve for event-free survival by
early response to dexamethasone treatment. The events are aban-
donment or death during induction and after complete remission,
also resistant disease and relapse. The continuous line represents
good responders (n = 133) and the dashed line represents poor
responders (n = 32).
of peripheral lymphoblasts, the greater the risk for adverse
events.
A Dutch study showed that laboratory in vitro resistance
to prednisolone was associated with a worse outcome [28].
The frequency of poor responder patients with peripheral
lymphoblasts 1000/µL or more after 7-day prednisone treat-
ment and 1 dose of intrathecal MTX at day 1 ranged from
7.5% to 15% in European studies [29, 30], while in our study
the poor responder rate was 19%. The diﬀerence may be
explained by delay in administrating intrathecal MTX, dif-
ferent steroid, slower steroid escalation, and high percentage
of early death and abandonment in our study. The steroid
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Table 3: Univariate and multivariate analyses of factors predicting
disease-free survival.
Factors HR 95% CI P value
Univariate analyses
Age at diagnosis 2.641 1.32–5.26 0.006
WBC group at diagnosis 1.992 1.06–3.74 0.03
Early response to treatment 2.023 1.04–3.92 0.04
Gender 0.894 0.52–1.53 0.67
Multivariate analysisa
Age at diagnosis 2.63 1.32–5.26 0.006
a
Final model. Age at diagnosis, WBC group, and early response were in-
cluded as factors in a stepwise analysis. Note that all three were also factors to
stratify patient into the HR group. The samemodel was found using forward
selection.
1For age <1 and ≥10 years relative to 1–9 years.
2For WBC ≥ 50,000 relative to WBC < 50,000.
3For poor responders relative to good responders.
4For girls relative to boys.
Table 4: Univariate and multivariate analyses of factors predicting
event-free survival.
Factors HR 95% CI P value
Univariate analyses
Age at diagnosis 2.051 1.31–3.22 0.02
WBC group at diagnosis 1.982 1.34–2.92 0.01
Early response to treatment 1.913 1.25–2.91 0.03
Gender 1.034 0.72–1.46 0.87
Multivariate analysisa
Age at diagnosis 1.75 1.10–2.79 0.018
WBC group at diagnosis 1.77 1.18–2.66 0.006
a
Final model. Age at diagnosis, WBC group, and early response were in-
cluded as factors in a stepwise analysis. All three were also used for stratifi-
cation into HR group. The model was found using forward selection.
1For age <1 and ≥10 years relative to 1–9 years.
2For WBC ≥ 50,000 relative to WBC < 50,000.
3For poor responders relative to good responders.
4For girls relative to boys.
used in our study was dexamethasone 6mg/m2 instead
of prednisone 60mg/m2 or prednisolone as used in those
the Western country. In our situation the intrathecal MTX
administration was not always given on day 1 as scheduled.
A European Organization for Research and Treatment of
Cancer (EORTC) study published by Thyss et al. [31] showed
that postponing intrathecal MTX injection generated an
increasing percentage of poor responder patients, that was
9.6% if intrathecal MTX injection was given before day 2,
but rose to 23.1% if it was given between day 2 and day 6, and
even to 30% if it was given at day 6 or after. So, we assumed
that the noticeable higher number of poor responder patients
in our study may have been due to postponing intrathecal
MTX injection. The role of the lymphoblast lineage is also
important in the response to steroids and MTX treatment
[23, 24]. Laboratory in vitro studies reveal that T-cell ALL
has lower sentivity to corticosteroids and MTX than B-cell
ALL [32, 33]. Whether the poor responders in our study
were more often T-ALL cases could not be confirmed due to
lack of immunophenotypic data, which were not yet available
during the Indonesian WK-ALL-2000 protocol.
Studies in Western countries revealed that the poor
responder patients were significantly associated with unfa-
vorable outcome with respect to DFS and EFS [11]. Our
study confirmed it for EFS only and not for DFS. Uni-
variate analysis shows that poor response is associated with
increased chance of induction failures and worse DFS and
EFS, suggesting that the measurement could be used in
a risk-based treatment for childhood acute lymphoblastic
leukemia. However, this study failed to demonstrate a
significantly added prognostic value for this factor over other
known risk factors for DFS and only a moderate added
prognostic value for EFS. One has to bear in mind however,
that we used poor response as a stratification factor, that is,
the poor responders got a more intensive treatment, which
might have resulted in higher DFS. For DFS age remained the
most important risk factor, whereas age andWBC count were
identified as significant predictors for EFS. So we suggest
that all these factors together with early response are taken
into account in a risk-based treatment for childhood acute
lymphoblastic leukemia. Our study confirmed the role of
morphology in evaluating the early response to treatment
for countries with limited economic resources and with high
rate of treatment abandonment contributed significantly for
treatment outcomes.
Significantly higher induction failures (including death
and abandonment) and resistant disease at the end of induc-
tion were shown in the poor responder group. Although
the poor responders did worse in induction, our study
failed to show significantly that poor responder patients
had a higher relapse rate and shorter period to experience
relapse as first event after achieving remission. In comparison
to the Dutch study with relapses in 14% cases [34], our
study showed an almost 3-fold higher relapse rate. This
could be explained due to our less intensive protocol but
particularly due to low adherence to the protocol [35, 36].
Quite often there was no medicine available or no money
for medicine, so many patients got (far) less than the
scheduled doses especially in the maintenance phase. Our
less intensive protocol and low adherence to it may explain
why most relapses occurred during treatment in our study.
Low EFS in our study was also caused by a high toxic
death rate (22%, 36/165) and abandonment (22%, 37/165)
during induction and remission. Both adverse events have a
significant contribution to failure in our treatment protocol
as reported by Mostert et al. [37] and studies from other
low-income countries [38, 39]. Social and economical factors
related to poor protocol compliance were also reported
in our hospital [35–37]. This is contrary to the western
countries where toxic death is approximately 2–5% and
abandonment is virtually unknown [40, 41].
We conclude that the frequency of poor responder
patients in Indonesia with dexamethasone as steroid and one
dose of intrathecal MTX is higher than found in most large
and well-reported Western studies. It has a strong predictive
value for induction failure and for resistant disease and is
associated with poorer outcome than the good responder
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patients. This measurement is practical, noninvasive, and
aﬀordable. Early response to treatment is thus not only
in high income countries, but even more in low-income
country a very useful means of improving stratification for
children with ALL in addition to the NCI-Rome criteria.
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